Your browser is no longer supported. Please, upgrade your browser.
ARDX [NASD]
Ardelyx, Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own1.30% Shs Outstand91.00M Perf Week0.74%
Market Cap658.15M Forward P/E- EPS next Y-0.73 Insider Trans9.82% Shs Float88.91M Perf Month-21.59%
Income-94.30M PEG- EPS next Q-0.35 Inst Own81.70% Short Float9.99% Perf Quarter-6.09%
Sales7.60M P/S86.60 EPS this Y28.50% Inst Trans0.05% Short Ratio4.15 Perf Half Y17.47%
Book/sh1.39 P/B4.88 EPS next Y48.20% ROA-44.20% Target Price- Perf Year-5.56%
Cash/sh1.92 P/C3.53 EPS next 5Y30.00% ROE-66.00% 52W Range4.96 - 9.23 Perf YTD4.95%
Dividend- P/FCF- EPS past 5Y4.00% ROI-51.30% 52W High-26.44% Beta1.96
Dividend %- Quick Ratio6.90 Sales past 5Y-20.60% Gross Margin98.10% 52W Low36.90% ATR0.54
Employees129 Current Ratio6.90 Sales Q/Q-21.70% Oper. Margin- RSI (14)43.14 Volatility5.82% 7.17%
OptionableYes Debt/Eq0.40 EPS Q/Q-12.10% Profit Margin- Rel Volume0.60 Prev Close6.64
ShortableYes LT Debt/Eq0.37 EarningsMay 06 BMO Payout- Avg Volume2.14M Price6.79
Recom1.40 SMA20-10.88% SMA50-5.74% SMA2005.72% Volume1,291,641 Change2.26%
Mar-23-21Initiated Wedbush Outperform $14
Jan-06-21Initiated Cantor Fitzgerald Overweight $14
Oct-20-20Resumed Citigroup Buy $13
Feb-18-20Resumed Jefferies Buy $11
Feb-12-20Initiated Citigroup Buy $13
Feb-10-20Initiated Cowen Outperform
Apr-08-19Initiated Piper Jaffray Overweight $15
Aug-24-18Initiated Jefferies Buy $7
Mar-19-18Resumed Leerink Partners Outperform $13
Nov-29-17Reiterated Citigroup Buy $16 → $17
Nov-22-17Reiterated Ladenburg Thalmann Buy $19 → $16
Oct-17-17Resumed Leerink Partners Outperform
Mar-31-16Initiated Ladenburg Thalmann Buy
Mar-09-16Initiated Cantor Fitzgerald Buy $19
Mar-03-16Initiated Citigroup Buy
May-13-21 01:12AM  
01:10AM  
May-06-21 09:35AM  
08:00AM  
Apr-30-21 11:25AM  
Apr-29-21 05:06PM  
04:15PM  
Apr-16-21 04:01PM  
08:32AM  
Apr-14-21 03:00PM  
08:00AM  
Apr-12-21 08:00AM  
Apr-07-21 01:46AM  
Apr-01-21 08:59AM  
Mar-30-21 04:01PM  
Mar-26-21 02:34PM  
Mar-15-21 08:00AM  
Mar-08-21 09:25AM  
08:00AM  
Mar-02-21 12:29AM  
Mar-01-21 07:04PM  
Feb-26-21 12:30PM  
Feb-17-21 08:00AM  
Feb-08-21 10:11AM  
Jan-16-21 01:34AM  
Dec-18-20 08:28PM  
Dec-11-20 12:58AM  
Nov-23-20 08:00AM  
Nov-10-20 08:00AM  
Nov-06-20 08:00AM  
05:28AM  
Nov-05-20 08:00AM  
Oct-28-20 12:33PM  
Oct-22-20 10:00AM  
08:00AM  
Oct-12-20 08:00AM  
Oct-02-20 07:02AM  
Sep-29-20 11:23AM  
Sep-15-20 08:00AM  
Sep-08-20 08:00AM  
Aug-27-20 08:41AM  
Aug-06-20 11:45AM  
08:00AM  
Aug-03-20 10:55AM  
08:00AM  
Jul-28-20 07:55AM  
Jul-08-20 12:00PM  
Jun-30-20 08:00AM  
Jun-28-20 08:30AM  
Jun-19-20 12:45PM  
Jun-15-20 08:00AM  
Jun-09-20 08:45PM  
Jun-08-20 04:01PM  
May-26-20 09:00AM  
May-21-20 05:23PM  
May-18-20 04:01PM  
May-12-20 10:44AM  
May-11-20 12:00PM  
May-10-20 08:16AM  
May-07-20 04:02PM  
Apr-28-20 12:00PM  
Apr-23-20 06:14AM  
Apr-17-20 07:30AM  
Mar-16-20 09:00AM  
Mar-09-20 08:15AM  
Mar-06-20 05:15PM  
04:02PM  
Feb-26-20 12:30PM  
08:00AM  
Feb-19-20 08:00AM  
Dec-31-19 05:16AM  
Dec-05-19 07:14AM  
Dec-04-19 11:32PM  
04:56PM  
07:06AM  
Dec-03-19 08:18AM  
07:45AM  
07:25AM  
Dec-02-19 04:01PM  
Nov-27-19 07:26AM  
Nov-26-19 04:00PM  
08:06AM  
Nov-25-19 06:00PM  
Nov-06-19 04:05PM  
04:02PM  
Nov-01-19 06:13AM  
Oct-10-19 04:00PM  
Sep-26-19 08:20AM  
Sep-19-19 02:31PM  
Sep-17-19 04:01PM  
Sep-13-19 12:29PM  
11:08AM  
08:24AM  
07:40AM  
Sep-12-19 03:12PM  
07:38AM  
Sep-11-19 05:47PM  
Sep-04-19 04:42PM  
12:07PM  
12:00PM  
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosenbaum David P.Chief Development OfficerApr 06Sale8.005,00040,000160,047Apr 08 06:20 PM
Blanks RobertSee RemarksFeb 22Sale6.885934,081112,729Feb 24 04:50 PM
Jacobs Jeffrey WChief Scientific OfficerFeb 22Sale6.887024,832124,772Feb 24 04:41 PM
Rosenbaum David P.Chief Development OfficerFeb 22Sale6.881931,32829,969Feb 24 04:38 PM
Rosenbaum David P.Chief Development OfficerFeb 22Sale6.886124,212165,047Feb 24 04:38 PM
Rodriguez SusanChief Commercial OfficerFeb 22Sale6.886114,20545,914Feb 24 04:40 PM
Renz Justin AChief Financial OfficerFeb 22Sale6.886084,18541,290Feb 24 04:37 PM
RAAB MICHAELPresident & CEOFeb 22Sale6.882,53417,440217,288Feb 24 04:39 PM
GRAMMER ELIZABETH ASee RemarksFeb 22Sale6.885043,469103,420Feb 24 04:36 PM
Jacobs Jeffrey WChief Scientific OfficerDec 21Sale6.883,94927,15392,862Dec 22 04:10 PM
GRAMMER ELIZABETH ASee RemarksDec 14Option Exercise2.3241,00095,120113,527Dec 15 04:22 PM
GRAMMER ELIZABETH ASee RemarksDec 14Sale7.3041,000299,30072,527Dec 15 04:22 PM
GRAMMER ELIZABETH ASee RemarksDec 11Option Exercise2.321,0002,32073,527Dec 15 04:22 PM
GRAMMER ELIZABETH ASee RemarksDec 11Sale7.301,0007,30072,527Dec 15 04:22 PM
MOTT DAVID MDirectorDec 10Buy5.89170,0001,000,841417,284Dec 10 06:22 PM
Rodriguez SusanChief Commercial OfficerSep 16Sale6.116,08737,16413,913Sep 17 06:35 PM
Jacobs Jeffrey WSVP, Technical OperationsSep 16Sale6.0510,00060,50096,811Sep 17 06:30 PM
Rosenbaum David P.Chief Development OfficerSep 15Sale5.513,47019,13121,662Sep 17 06:34 PM
Rosenbaum David P.Chief Development OfficerSep 15Sale5.5234,656191,301133,047Sep 17 06:34 PM
Blanks RobertSee RemarksSep 15Sale5.4534,685189,18280,710Sep 17 06:33 PM
RAAB MICHAELPresident & CEOSep 15Sale5.61106,337596,285104,720Sep 17 06:31 PM
Renz Justin AChief Financial OfficerSep 15Sale5.493,71420,3739,286Sep 17 06:32 PM
GRAMMER ELIZABETH ASee RemarksSep 15Sale5.3728,810154,57472,527Sep 17 06:31 PM
Jacobs Jeffrey WSVP, Technical OperationsSep 15Sale5.5340,804225,589106,811Sep 17 06:30 PM
Blanks RobertSee RemarksSep 01Sale5.582,04911,425115,395Sep 03 05:03 PM
RAAB MICHAELPresident & CEOJul 02Sale7.0123,128162,13024,364Jul 06 04:47 PM
MOTT DAVID MDirectorJun 25Buy6.9668,373476,040247,284Jun 26 04:19 PM
MOTT DAVID MDirectorJun 24Buy6.7572,598489,862178,911Jun 26 04:19 PM
MOTT DAVID MDirectorJun 22Buy6.754,67331,525106,313Jun 24 06:49 PM
BASKETT FOREST10% OwnerJun 15Sale6.37432740Jun 17 04:00 PM
SANDELL SCOTT D10% OwnerJun 15Sale6.37432740Jun 17 04:00 PM
SANDELL SCOTT D10% OwnerJun 12Sale6.4244,992288,68243Jun 12 05:40 PM
BASKETT FOREST10% OwnerJun 12Sale6.4244,992288,68243Jun 12 05:38 PM
SANDELL SCOTT D10% OwnerJun 11Sale6.3244,991284,46545,035Jun 12 05:40 PM
BASKETT FOREST10% OwnerJun 11Sale6.3467,891430,3330Jun 12 05:38 PM
RAAB MICHAELPresident & CEOJun 01Sale7.3323,128169,63546,257Jun 02 06:38 PM